Replies to post #148163 on Biotech Values

[DewDiligence]

VRX management may be suffering from megalomania—they have just acquired Visudyne from QLTI for $112.5M, suggesting that the roll-up business model is out of control:

http://finance.yahoo.com/news/valeant-pharmaceuticals-acquires-visudyne-qlt-113000598.html

Visudyne is a barbaric relic of the 1990s.